Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H19N7O6.2H2O |
| Molecular Weight | 477.428 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N2)C(=O)N1
InChI
InChIKey=ODYNNYOEHBJUQP-LTCKWSDVSA-N
InChI=1S/C19H19N7O6.2H2O/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28;;/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30);2*1H2/t12-;;/m0../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H19N7O6 |
| Molecular Weight | 441.3975 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/ja01853a512 | https://www.ncbi.nlm.nih.gov/pubmed/28031963 | https://www.ncbi.nlm.nih.gov/pubmed/1560436
Curator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/ja01853a512 | https://www.ncbi.nlm.nih.gov/pubmed/28031963 | https://www.ncbi.nlm.nih.gov/pubmed/1560436
Folic Acid is a B complex vitamin containing a pteridine moiety linked by a methylene bridge to para-aminobenzoic acid, which is joined by a peptide linkage to glutamic acid. Conjugates of Folic Acid are present in a wide variety of foods, particularly liver, kidneys, yeast and leafy green vegetables. Commercially available Folic Acid is prepared synthetically. Folic Acid occurs as a yellow or yellowish-orange crystalline powder and is very slightly soluble in water and insoluble in alcohol. Aqueous solutions of Folic Acid are heat sensitive and rapidly decompose in the presence of light and/or riboflavin; solutions should be stored in a cool place protected from light. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Folic Acid is relatively nontoxic in man. Rare instances of allergic responses to Folic Acid preparations have been reported and have included erythema, skin rash, itching, general malaise, and respiratory difficulty due to bronchospasm. Endocyte is developing an intravenous (IV) formulation of folic acid, called Neocepri®, which is intended for the diagnosis of positive folate receptor-positive status in patients with ovarian cancer when administered prior to the radioactive medicine, technetium Tc99m Etarfolatide. The benefits of Neocepri® are its ability to reduce the background activity observed on single photon emission computed tomography (SPECT) imaging in most normal, nontarget tissues (e.g. intestines, liver, kidney, spleen), thereby improving the image quality of the scans. The product had been granted orphan drug designation in the EU. Endocyte had filed a conditional marketing authorization application (CMA) with the European Medicines Agency (EMA) for Neocepri®.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006760 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FOLVITE Approved UseIndications and Usage. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Launch Date1947 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. | 1994 Nov 14 |
|
| Up-regulation of galectin-3 in acute renal failure of the rat. | 2000 Sep |
|
| Rationale for risk reduction of cardiovascular disease using homocysteine concentration in blood and plasma as biomarker: support by clinical data. | 2001 |
|
| Folic acid and neural tube defects. | 2001 |
|
| A bifunctional dihydrofolate synthetase--folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. | 2001 Feb |
|
| Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. | 2001 Feb |
|
| Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. | 2001 Feb |
|
| Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. | 2001 Feb |
|
| Analysis of uracil DNA glycosylase in human colorectal cancer. | 2001 Feb |
|
| Lowered weight gain during pregnancy and risk of neural tube defects among offspring. | 2001 Feb |
|
| Folate reception by vegetative Dictyostelium discoideum amoebae: distribution of receptors and trafficking of ligand. | 2001 Feb |
|
| Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. | 2001 Feb |
|
| Homocysteine metabolism in renal failure. | 2001 Feb |
|
| Changes in markers of anemia and iron metabolism and how they are influenced by antianemics in postpartum period. | 2001 Feb |
|
| C677T variant form at the MTHFR gene and CL/P: a risk factor for mothers? | 2001 Feb 1 |
|
| It's just a vitamin.. | 2001 Feb 1 |
|
| Lack of clinical utility of folate levels in the evaluation of macrocytosis or anemia. | 2001 Feb 1 |
|
| Bioactivity of [6R]-5-formyltetrahydrofolate, an unusual isomer, in humans and Enterococcus hirae, and cytochrome c oxidation of 10-formytetrahydrofolate to 10-formyldihydrofolate. | 2001 Feb 15 |
|
| Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. | 2001 Feb 20 |
|
| [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options]. | 2001 Jan |
|
| Homocysteine--a novel risk factor for vascular disease. | 2001 Jan |
|
| SLATE: a method for the superposition of flexible ligands. | 2001 Jan |
|
| Preconceptual folic acid: opportunity for preconceptual counseling offers opportunity to help prevent neural tube defects. | 2001 Jan |
|
| Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients. | 2001 Jan |
|
| Intravenous infusion of iron and tetrahydrofolate does not influence intrauterine uteroferrin and secreted folate-binding protein content in swine. | 2001 Jan |
|
| Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. | 2001 Jan |
|
| Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. | 2001 Jan |
|
| Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells. | 2001 Jan |
|
| Maternal plasma homocysteine levels in women with preterm premature rupture of membranes. | 2001 Jan |
|
| Hyperhomocysteinaemia in young adults is not associated with impaired endothelial function. | 2001 Jan |
|
| Folic acid and miscarriage: an unjustified link. | 2001 Jan 15 |
|
| Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. | 2001 Jan 2 |
|
| Subnormal concentrations of serum cobalamin (vitamin B12) in cats with gastrointestinal disease. | 2001 Jan-Feb |
|
| Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. | 2001 Mar |
|
| Knowledge on periconceptional use of folic acid in women of British Columbia. | 2001 Mar-Apr |
Patents
Sample Use Guides
Usual Adult Dose for Megaloblastic Anemia: 1 mg orally, intramuscularly, subcutaneously or IV once a day.
Nutritional Supplementation (Recommended daily allowance): Males: 400 mkg/day, Females: 400-800 mkg/day, Pregnant women: 600 mkg/day, Nursing women: 500 mkg/day, Upper limit: 1 mg/day.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:21:19 GMT 2025
by
admin
on
Mon Mar 31 23:21:19 GMT 2025
|
| Record UNII |
0S1T5C0JZL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135564683
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY | |||
|
DTXSID20273931
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY | |||
|
75708-92-8
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY | |||
|
0S1T5C0JZL
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
![Structure of (2S)-2-[4-[bis[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzamido]pentanedioic acid](/img/8bae2c60-6f0d-4c71-8754-94a461c7e0e7.svg "Structure of (2S)-2-[4-[bis[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzamido]pentanedioic acid")
![Structure of N-[4-[(2-Amino-3,4-dihydro-7-methyl-4-oxo-6-pteridinyl)amino]benzoyl]-L-glutamic acid](/img/795e0609-2331-4292-bd47-b5a05d51c584.svg "Structure of N-[4-[(2-Amino-3,4-dihydro-7-methyl-4-oxo-6-pteridinyl)amino]benzoyl]-L-glutamic acid")
![Structure of N-[4-[[(4S)-4-[[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-4-carboxy-1-oxobutyl]amino]benzoyl]-L-glutamic acid](/img/f24ccfaf-0e11-4fca-818c-fb399349de15.svg "Structure of N-[4-[[(4S)-4-[[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-4-carboxy-1-oxobutyl]amino]benzoyl]-L-glutamic acid")
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |